User profiles for C. Lieu
Christopher LieuUNIVERSITY OF COLORADO Verified email at cuanschutz.edu Cited by 7882 |
Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists …
… There is insufficient evidence to recommend BRAF c.1799 p.V600 mutational status as a
predictive molecular biomarker for response to anti-EGFR inhibitors. No recommendation …
predictive molecular biomarker for response to anti-EGFR inhibitors. No recommendation …
Characteristics of early-onset vs late-onset colorectal cancer: a review
Importance The incidence of early-onset colorectal cancer (younger than 50 years) is rising
globally, the reasons for which are unclear. It appears to represent a unique disease process …
globally, the reasons for which are unclear. It appears to represent a unique disease process …
[HTML][HTML] ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper
…, SA Jacobs, HF Kennecke, JJ Lee, CH Lieu… - Nature reviews Clinical …, 2020 - nature.com
… at progressively increasing speeds (800–1,600 g) at 4C or through filtration followed by
immediate deep freezing (typically at –80C) 20,21,22 . Immune cells obtained from the buffy coat …
immediate deep freezing (typically at –80C) 20,21,22 . Immune cells obtained from the buffy coat …
Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Neuroendocrine
and Adrenal Gland Tumors focus on the diagnosis, treatment, and management of patients …
and Adrenal Gland Tumors focus on the diagnosis, treatment, and management of patients …
[HTML][HTML] Treatment of metastatic colorectal cancer: ASCO guideline
… OS (coprimary outcome) at data cutoff (median 32.4 months) HR, 0.74 (95% CI 0.53 to
1.03) 34 (296 patients in one study) 448 deaths per 1,000 356 deaths per 1,000 Low a,b,c …
1.03) 34 (296 patients in one study) 448 deaths per 1,000 356 deaths per 1,000 Low a,b,c …
[HTML][HTML] Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated …
… (C) Progression-free survival for patients with interleukin-8 levels above and below the … a
lesser extent with stem cell factor (SCF)/c-kit ligand, with average levels returning to normal at …
lesser extent with stem cell factor (SCF)/c-kit ligand, with average levels returning to normal at …
Neuroendocrine tumors, version 1.2015
Neuroendocrine tumors (NETs) comprise a broad family of tumors that may or may not be
associated with symptoms attributable to hormonal hypersecretion. The NCCN Clinical …
associated with symptoms attributable to hormonal hypersecretion. The NCCN Clinical …
Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer
BACKGROUND: It is hypothesized that BRAF mutant cancers represent a discrete subset of
metastatic colorectal cancer (CRC) defined by poorer survival. This study investigates …
metastatic colorectal cancer (CRC) defined by poorer survival. This study investigates …
Somatic genomic testing in patients with metastatic or advanced cancer: ASCO provisional clinical opinion
…, J Perlmutter, SW Gray, J Hwang, C Lieu… - Journal of Clinical …, 2022 - ingentaconnect.com
PURPOSE An ASCO provisional clinical opinion offers timely clinical direction to ASCO's
membership following publication or presentation of potentially practice-changing data from …
membership following publication or presentation of potentially practice-changing data from …
NCCN guidelines insights: neuroendocrine and adrenal tumors, version 2.2018
The NCCN Guidelines for Neuroendocrine and Adrenal Tumors provide recommendations
for the management of adult patients with neuroendocrine tumors (NETs), adrenal gland …
for the management of adult patients with neuroendocrine tumors (NETs), adrenal gland …